Milestone Pharmaceuticals (MIST) announced that the U.S. Food and Drug Administration, FDA, approved its first commercial product, CARDAMYST nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, PSVT, to sinus rhythm in adults. This approval marks the first time that more than two million Americans with PSVT will have a rapid-acting treatment option they can self-administer outside the emergency department or other healthcare setting. CARDAMYST is expected to be available in retail pharmacies in the first quarter of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals trading halted, news pending
- Milestone Pharmaceuticals: Buy Rating Reaffirmed Amid Imminent PDUFA Date and Misunderstood CRL Implications
- Milestone Pharmaceuticals Reports Q3 2025 Financial Results
- Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth
- Milestone Pharmaceuticals: Positioned for Success with Cardamyst’s Potential Approval and Launch